Australia's Neurizon Therapeutics jumps on deal with US firm

Neurizon Therapeutics

17/06/2026 04:38

** Shares of biotech company Neurizon Therapeutics NUZ.AX jump 12.7% to A$0.071, their highest level since May 18
** On track for best day since Jan 23
** Co signs long-term supply agreement with U.S.-listed Elanco Animal Health ELAN.N for an initial term of five years
** Secures access to human health monepantel, the active pharmaceutical ingredient in its lead asset, NUZ-001
** Stock down 16.5% YTD, including moves in current session

(Reporting by Jasmeen Ara Shaikh in Bengaluru)
((Jasmeenaraislam.Shaikh@thomsonreuters.com;))